Insulin pump therapy in neonatal diabetes

Area of Science:

• Pediatrics
• Endocrinology
• Metabolic Disorders

Background:

• Neonatal diabetes mellitus is a rare condition characterized by hyperglycemia in infants within the first six weeks of life.
• Managing insulin therapy in newborns presents significant challenges due to difficulties in precise insulin delivery and the risk of hypoglycemia.
• Limited data exist on effective insulin delivery methods for neonatal diabetes, necessitating further investigation into advanced therapeutic approaches.

Purpose of the Study:

• To evaluate the safety, efficacy, and manageability of continuous subcutaneous insulin infusion (CSII) in infants with neonatal diabetes mellitus.
• To compare CSII with traditional insulin injections for managing very small insulin doses and complex feeding regimens in neonates.
• To assess the long-term outcomes and tolerability of CSII in infants requiring insulin therapy for over 15 days.

Main Methods:

• Retrospective analysis of 18 years of data on 17 infants with neonatal diabetes requiring insulin therapy for more than 15 days.
• Implementation of CSII with specific protocols for insulin dilution (5-10 U/ml) to manage microdoses (e.g., 0.20 U bolus, 0.02 U/h basal).
• Adaptation of CSII basal and bolus rates to accommodate continuous enteral/parenteral feeding and intermittent bottle feeding schedules.

Main Results:

• CSII enabled precise adaptation of insulin delivery to match infant feeding regimens, including basal rates for continuous feeding and preprandial boluses for intermittent feeds.
• Accurate administration of very small insulin doses was achieved through insulin dilution and CSII, surpassing the precision of traditional syringes.
• CSII demonstrated efficient blood glucose control with a reduced incidence of hypoglycemia compared to injections, and infants tolerated infusion lines well without adverse effects.

Conclusions:

• Continuous subcutaneous insulin infusion (CSII) is a safe, physiological, and accurate method for managing neonatal diabetes during the neonatal period.
• CSII simplifies insulin therapy management by allowing precise adjustments to insulin delivery, facilitating better glycemic control and matching infant nutritional needs.
• Under experienced team supervision, CSII is a superior alternative to injections for infants requiring long-term insulin therapy for neonatal diabetes.